Pay in 4 interest-free payments of $6.37 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for the treatment of type 2 diabetes mellitus (under the brand name Ozempic) and chronic weight management (as Wegovy)
The estimated annual cost of providing GLP-1RAs to all indicated patients would be $3.35 to $5.31 billion at pre-generic 2025 semaglutide prices
Dispose of the pen 30 days after first use
Litigation against the manufacturer of Rybelsus, Novo Nordisk, remains ongoing with lawsuits continuing to be filed across the country
The diabetic subpopulation consists of individuals with a documented history of diabetes mellitus (excluding prediabetes), based on diagnosis codes available from 2015 onward
US$ 27.37
US$ 27.15
US$ 20.36
